PL3342786T3 - Przeciwciało przeciwko dll3 - Google Patents

Przeciwciało przeciwko dll3

Info

Publication number
PL3342786T3
PL3342786T3 PL18156974T PL18156974T PL3342786T3 PL 3342786 T3 PL3342786 T3 PL 3342786T3 PL 18156974 T PL18156974 T PL 18156974T PL 18156974 T PL18156974 T PL 18156974T PL 3342786 T3 PL3342786 T3 PL 3342786T3
Authority
PL
Poland
Prior art keywords
antibody against
against dll3
dll3
antibody
Prior art date
Application number
PL18156974T
Other languages
English (en)
Inventor
Kenji Yoshida
Hiroyuki Aburatani
Shumpei Ishikawa
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
The University Of Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3342786(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Seiyaku Kabushiki Kaisha, The University Of Tokyo filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of PL3342786T3 publication Critical patent/PL3342786T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
PL18156974T 2010-01-29 2011-01-28 Przeciwciało przeciwko dll3 PL3342786T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010019391 2010-01-29
PCT/JP2011/000485 WO2011093097A1 (ja) 2010-01-29 2011-01-28 抗dll3抗体
EP18156974.0A EP3342786B1 (en) 2010-01-29 2011-01-28 Anti-dll3 antibody
EP11736812.6A EP2530091B1 (en) 2010-01-29 2011-01-28 Anti-dll3 antibody

Publications (1)

Publication Number Publication Date
PL3342786T3 true PL3342786T3 (pl) 2021-12-20

Family

ID=44319091

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18156974T PL3342786T3 (pl) 2010-01-29 2011-01-28 Przeciwciało przeciwko dll3
PL11736812T PL2530091T3 (pl) 2010-01-29 2011-01-28 Przeciwciało przeciwko dll3

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11736812T PL2530091T3 (pl) 2010-01-29 2011-01-28 Przeciwciało przeciwko dll3

Country Status (14)

Country Link
US (4) US9127071B2 (pl)
EP (3) EP3342786B1 (pl)
JP (1) JP5918540B2 (pl)
DK (2) DK2530091T3 (pl)
ES (2) ES2889932T3 (pl)
HR (2) HRP20180952T1 (pl)
HU (2) HUE038962T2 (pl)
LT (2) LT2530091T (pl)
PL (2) PL3342786T3 (pl)
PT (2) PT3342786T (pl)
RS (2) RS57412B1 (pl)
SI (2) SI2530091T1 (pl)
TR (1) TR201806936T4 (pl)
WO (1) WO2011093097A1 (pl)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10611835B2 (en) * 2008-07-10 2020-04-07 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancer
LT2530091T (lt) 2010-01-29 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antikūnas
EP3093294A1 (en) 2012-02-24 2016-11-16 Stemcentrx, Inc. Dll3 modulators and methods of use
EP2832856A4 (en) 2012-03-29 2016-01-27 Chugai Pharmaceutical Co Ltd ANTI-LAMP5 ANTIBODIES AND USE THEREOF
GB201302447D0 (en) * 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
RU2019109456A (ru) 2013-02-22 2019-04-10 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые конъюгаты антител и их применения
EA201591750A1 (ru) 2013-03-14 2016-05-31 Дженентек, Инк. Антитела против b7-h4 и иммуноконъюгаты
US9562099B2 (en) * 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
JP6824735B2 (ja) 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
WO2015031698A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Site-specific antibody conjugation methods and compositions
KR20160047567A (ko) * 2013-08-28 2016-05-02 스템센트알엑스 인코포레이티드 조작된 항-dll3 접합체 및 사용 방법
JP2016538318A (ja) 2013-08-28 2016-12-08 ステムセントリックス， インコーポレイテッド 新規ｓｅｚ６モジュレーターおよび使用方法
SG10201802525QA (en) 2013-09-13 2018-04-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
KR102332302B1 (ko) * 2013-09-13 2021-12-01 제넨테크, 인크. 세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
CN105940107B (zh) 2013-11-11 2021-06-15 中外制药株式会社 含有改变了抗体可变区的抗原结合分子
KR20170008202A (ko) 2014-02-21 2017-01-23 애브비 스템센트알엑스 엘엘씨 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
CA2956072A1 (en) 2014-07-21 2016-01-28 Bloodworks Antibodies that recognize red blood cell antigens
ES2743809T3 (es) 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
US10059768B2 (en) 2014-09-12 2018-08-28 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
TWI740809B (zh) 2014-11-11 2021-10-01 日商中外製藥股份有限公司 包含經改變之抗體可變區之抗原結合分子的資料庫
MA41613A (fr) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
CA3024723A1 (en) 2016-05-20 2017-11-23 Robert B. Dubridge Single domain serum albumin binding protein
PL3431105T3 (pl) 2017-03-29 2020-11-02 Shionogi & Co., Ltd. Kompozycja lecznicza do leczenia raka
US11021540B2 (en) * 2017-09-07 2021-06-01 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
JP7084990B2 (ja) 2017-10-13 2022-06-15 ハープーン セラピューティクス，インク． 三重特異性タンパク質と使用方法
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
EP3720963A4 (en) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE WITH CHANGED BINDING OF THE VARIABLE ANTIBODY REGIONS CD3 AND CD137
WO2019131988A1 (en) 2017-12-28 2019-07-04 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
BR112020021280A2 (pt) 2018-05-08 2021-01-26 Phanes Therapeutics, Inc. anticorpos anti-dll3 e usos dos mesmos
WO2019222283A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN113286824A (zh) 2018-08-03 2021-08-20 中外制药株式会社 包含两个彼此连接的抗原结合结构域的抗原结合分子
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113286817B (zh) * 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
EP3856789A4 (en) 2018-09-28 2022-08-17 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE WITH VARIABLE REGION OF AN ALTERED ANTIBODY
EP3927744A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
BR112021016272A2 (pt) * 2019-04-08 2021-11-09 Phanes Therapeutics Inc Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos
US12516128B2 (en) 2019-05-14 2026-01-06 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
BR112022000216A2 (pt) * 2019-07-11 2022-05-17 Memorial Sloan Kettering Cancer Center Anticorpos direcionados a dll3 e usos dos mesmos
US20220281998A1 (en) 2019-08-28 2022-09-08 Azusapharma Sciences, Inc. Bifidobacterium spp. expressing and secreting diabody-type bsab
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
CN115335410A (zh) 2020-03-31 2022-11-11 中外制药株式会社 生产多特异性抗原结合分子的方法
TWI799824B (zh) 2020-03-31 2023-04-21 日商中外製藥股份有限公司 Ｄｌｌ３靶向之多特異性抗原結合分子及其用途
CA3193569A1 (en) * 2020-09-28 2022-03-31 Xiaofeng Liu Anti-sclerostin constructs and uses thereof
AU2021372988A1 (en) * 2020-11-06 2023-06-22 Board Of Regents, The University Of Texas System Methods and systems for classification and treatment of small cell lung cancer
CA3204731A1 (en) 2021-01-13 2022-07-21 John T. POIRIER Anti-dll3 antibody-drug conjugate
TW202237135A (zh) 2021-01-13 2022-10-01 紀念斯隆凱特琳癌症中心 抗體-吡咯并苯并二氮呯衍生物結合物
JP2024534892A (ja) * 2021-09-02 2024-09-26 メモリアル スローン ケタリング キャンサー センター 抗ｄｌｌ３抗体及びその使用
CA3231586A1 (en) * 2021-09-17 2023-03-23 Yunying CHEN D3-binding molecules and uses thereof
WO2023053272A1 (en) 2021-09-29 2023-04-06 Chugai Seiyaku Kabushiki Kaisha Uses of dll3-targeting multispecific antigen-binding molecules
WO2023092082A1 (en) * 2021-11-18 2023-05-25 Bentley Cornelia Antibodies to receptor of advanced glycation end products (rage) and uses thereof
WO2023147470A2 (en) 2022-01-28 2023-08-03 Georgiamune Inc. Antibodies to programmed cell death protein 1 that are pd-1 agonists
JP2025523090A (ja) 2022-07-14 2025-07-17 メディリンク セラピューティクス（スーチョウ）カンパニー，リミティド 抗体薬物複合体及びその製造方法と使用
IL319125A (en) 2022-08-22 2025-04-01 Abdera Therapeutics Inc DLL3 binding molecules and their uses
CN120265651A (zh) 2022-11-25 2025-07-04 中外制药株式会社 用于生产蛋白质的方法
CN116813784B (zh) * 2023-05-17 2024-03-01 星奕昂(上海)生物科技有限公司 靶向dll3的抗体及其应用
WO2025036352A1 (zh) * 2023-08-14 2025-02-20 海南先声再明医药股份有限公司 特异性识别Delta样配体3的纳米抗体及其应用
TW202530259A (zh) * 2023-09-21 2025-08-01 大陸商樂普創一生物科技（上海）有限公司 抗ｄｌｌ３抗體及其用途
WO2025085761A1 (en) * 2023-10-19 2025-04-24 Harpoon Therapeutics, Inc. Dll3 targeting trispecific proteins and methods of use
TW202540179A (zh) * 2023-11-15 2025-10-16 美商西雅圖免疫公司 抗dll3抗體以及製造與使用其之方法
WO2026039940A1 (zh) * 2024-08-19 2026-02-26 南京博安生物技术有限公司 一种增强型靶向dll3蛋白的嵌合抗原受体和突变体以及应用
CN120590534A (zh) * 2025-02-27 2025-09-05 昕传生物科技(北京)有限公司 靶向dll3的抗体、嵌合抗原受体及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPS6459878A (en) 1987-08-31 1989-03-07 Matsushita Electric Industrial Co Ltd Semiconductor laser protective circuit
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
KR100261941B1 (ko) 1994-07-13 2000-07-15 나가야마 오사무 사람의 인터루킨-8에 대한 재구성 사람항체
AU6952498A (en) 1997-04-04 1998-10-30 Millenium Pharmaceuticals, Inc. Novel human delta3 compositions and therapeutic and diagnostic uses therefor
US20030180784A1 (en) 1997-04-04 2003-09-25 Millennium Pharmaceuticals, Inc. Novel human Delta3 compositions and therapeutic and diagnostic uses therefor
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
JP4139508B2 (ja) 1998-02-19 2008-08-27 旭化成株式会社 ヒトデルター３
JP4332581B2 (ja) 1998-02-19 2009-09-16 旭化成株式会社 ヒトデルタ−３
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
EP1159284A4 (en) 1999-02-10 2003-10-29 Human Genome Sciences Inc 33 HUMAN SECRETARY PROTEINS
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2001012664A2 (en) 1999-08-19 2001-02-22 Chiron Corporation Notch receptor ligands and uses thereof
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001280471A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Novel secreted proteins and their uses
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
JP2005500018A (ja) 2001-04-02 2005-01-06 アイデック ファーマスーティカルズ コーポレイション ＧｎＴＩＩＩと同時発現する組換え抗体
WO2003025138A2 (en) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US20050137130A1 (en) 2001-11-14 2005-06-23 Bodmer Mark W. Medical treatment
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
EP1594447A2 (en) 2002-10-02 2005-11-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040115204A1 (en) * 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
US7863042B2 (en) 2003-06-18 2011-01-04 Chugai Seiyaku Kabushiki Kaisha Fucose transporter
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
BRPI0620695A2 (pt) 2005-12-16 2011-11-22 Genentech, Inc método para tratar um tumor do tipo glioma, métodos de prognóstico e/ou diagnóstico de glioma, método de monitoramento ou diagnóstico, método para inibir o tamanho ou crescimento de um tumor do tipo glioma, métodos para tratar terapeuticamente, método para determinar o nìvel de expressão de marcadores determinantes de glioma ("gdm") de pn, prolif ou mes, método para prognosticar o tempo de sobrevida, método para diagnosticar a severidade de um tumor do tipo glioma e uso
WO2007080597A2 (en) * 2006-01-16 2007-07-19 Compugen Ltd. Polynucleotide and polypeptide sequences and methods for diagnosis
US20100061933A1 (en) 2006-10-20 2010-03-11 Naoki Kimura Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
DE602008006041D1 (de) 2007-01-30 2011-05-19 Forerunner Pharma Res Co Ltd CHIMÄRER Fc GAMMA REZEPTOR UND VERFAHREN ZUR BESTIMMUNG VON ADCC-AKTIVITÄT UNTER VERWENDUNG DES REZEPTORS
WO2009124931A2 (en) * 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
JP4787295B2 (ja) 2008-07-14 2011-10-05 株式会社トープラ 高強度セルフフォーミングねじによるねじ締結構造体
LT2530091T (lt) 2010-01-29 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antikūnas
EP3093294A1 (en) * 2012-02-24 2016-11-16 Stemcentrx, Inc. Dll3 modulators and methods of use
KR20170008202A (ko) * 2014-02-21 2017-01-23 애브비 스템센트알엑스 엘엘씨 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體

Also Published As

Publication number Publication date
HUE038962T2 (hu) 2018-12-28
PT3342786T (pt) 2021-09-24
PT2530091T (pt) 2018-05-17
EP2530091A4 (en) 2013-07-10
RS62387B1 (sr) 2021-10-29
ES2674420T3 (es) 2018-06-29
PL2530091T3 (pl) 2018-08-31
LT2530091T (lt) 2018-06-11
ES2889932T3 (es) 2022-01-14
US20120328624A1 (en) 2012-12-27
RS57412B1 (sr) 2018-09-28
EP2530091B1 (en) 2018-04-04
US9127071B2 (en) 2015-09-08
HUE056313T2 (hu) 2022-02-28
JP5918540B2 (ja) 2016-05-18
US20160244530A2 (en) 2016-08-25
DK3342786T3 (en) 2021-09-27
US20250236679A1 (en) 2025-07-24
EP3907242A1 (en) 2021-11-10
DK2530091T3 (en) 2018-05-28
HRP20211444T1 (hr) 2021-12-24
HRP20180952T1 (hr) 2018-07-27
LT3342786T (lt) 2021-10-25
SI2530091T1 (en) 2018-06-29
US11111311B2 (en) 2021-09-07
US20210380715A1 (en) 2021-12-09
EP2530091A1 (en) 2012-12-05
EP3342786A1 (en) 2018-07-04
EP3342786B1 (en) 2021-06-23
WO2011093097A1 (ja) 2011-08-04
TR201806936T4 (tr) 2018-06-21
SI3342786T1 (sl) 2022-01-31
JPWO2011093097A1 (ja) 2013-05-30
US20150368355A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
HUS2300021I1 (hu) Anti-IL-36R antitestek
LTC2635601I2 (lt) Antikūnai prieš il-23
PL3342786T3 (pl) Przeciwciało przeciwko dll3
LTC2579894I2 (lt) CGRP antikūnai
BR112012030311A2 (pt) anticorpo
IL223366B (en) Anti-cmet antibody
CO6811812A2 (es) Anticuerpo anti-b7-h3
EP2629796A4 (en) ANTIBODY
DK3178851T3 (da) Anti-cd40-antistoffer
IL231777A0 (en) Antibodies against tl1a and uses thereof
LT3284754T (lt) Antikūnai prieš cd38
CR20140127A (es) Anticuerpo anti-abtcr
EP2482848A4 (en) Endoglin antibodies
HUE039849T2 (hu) CD70 elleni ellenanyagok
DK2521736T3 (da) Humaniserede antistoffer
DK3275892T3 (da) Præfusions-rsv-f-antigener
DK3336225T3 (da) Antistofbiblioteker
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
PT2552242E (pt) Resumo
DK3620175T3 (da) Højkoncentrerede antistofformuleringer
SMT201600193B (it) Nuovo anticorpo anti-dr5
CO6791565A2 (es) Anticuerpos anti-notch1
DK2651436T3 (da) Mycobakterie antigen sammensætning.
HUE050858T2 (hu) VLA-4 ellenes antitestek
LT2742068T (lt) Nauji antikūnai prieš fosforilcholiną